Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

EQ vs MRK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRK Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

MRK Overall Winner 6-Pillar Tally: EQ 1 – 5 MRK Matrix Metrics: EQ 2 – 8 MRK

As of Nov 19, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over Equillium, Inc. (EQ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EQ carries a Unified Composite Score of 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin), whereas MRK carries 50.8/100 (HOLD) at $132.81 (14.8x Forward P/E, 35.2% operating margin).

  • Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile MRK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EQ vs MRK
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.53β · 93% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.8%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.33 · SMA50: $1.49
MRK NYSE Head-to-Head Winner
Merck & Co., Inc.
Pharmaceutical Preparations
$132.81
-3.61% 1D
Market Cap $339.7B
TTM Revenue $67.4B
Forward P/E 14.8x
Beta / 30D Vol 0.27β · 34% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.7%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $144.93 · SMA50: $145.48

6-Pillar Scorecard Institutional Category Breakdown (EQ 1 – 5 MRK)

Columns: Metric · EQ · MRK
1. Valuation Multiples EQ
Forward P/E 1.5x 14.8x
Trailing P/E 1.5x 139.2x
PEG Ratio N/M 3.47x
EV / Revenue 7.7x 5.7x
2. Growth & Scale MRK
Revenue Growth (YoY) -52.3% +4.7%
Earnings Growth (YoY) +0.0% -12.0%
TTM Revenue (USD) $4.4M $67.4B
Market Cap $90.6M $339.7B
3. Profitability & Quality MRK
Gross Margin 100.0% 75.2%
Operating Margin 0.0% 35.2%
Net Profit Margin 0.0% 3.6%
Return on Equity (ROE) -59.0% 5.1%
4. Balance Sheet & Cash Flow MRK
Cash Generation (TTM) -$20M $14.7B
Cash Flow Margin N/A 21.9%
Net Cash / Leverage $57M Net Cash $44.2B Net Debt (1.20x D/E)
Dividend Yield None (0.00%) 2.34%
5. Options & Positioning MRK
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 261.3% (100th %ile) 30.6% (28th %ile)
Put/Call OI Skew N/A 0.80x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MRK
OpEx & R&D Intensity N/A 40.0% of Rev ($27.0B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EQ (2) vs MRK (8)
Institutional Metric EQ MRK Criterion Row Edge
Market Capitalization
Scale
$90.6M $339.7B Larger Scale MRK
Trailing P/E Ratio
Valuation
1.5x 139.2x Lower Multiple EQ
Forward P/E Ratio
Valuation
1.5x 14.8x Lower Multiple EQ
Revenue Growth (YoY)
Growth
-52.3% +4.7% Higher Growth MRK
Operating Margin (TTM)
Profitability
0.0% 35.2% Higher Margin MRK
Net Profit Margin
Profitability
0.0% 3.6% Higher Margin MRK
Return on Equity (ROE)
Capital Efficiency
-59.0% 5.1% Higher ROE MRK
52-Week Range Position
Momentum
11% ($1–$4) 63% ($92–$157) Stronger Trend MRK
Beta / 30D Volatility
Risk Regime
1.53β · 93% Vol 0.27β · 34% Vol Lower Realized Risk MRK
Unified Institutional Score
Composite Signal
48.0 / 100 (HOLD) 50.8 / 100 (HOLD) Higher Composite MRK
Trailing 12M Revenue (USD)
Operating Scale
$4.4M $67.4B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 75.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.7x EV/Rev 3.47x PEG · 5.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$20M ($57M Net Cash) $14.7B ($44.2B Net Debt (1.20x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRK +9.74 pp
EQ: -21.13% · MRK: -11.39%
3M Horizon MRK +38.58 pp
EQ: -51.52% · MRK: -12.94%
6M Horizon MRK +63.93 pp
EQ: -49.32% · MRK: +14.61%
1Y Horizon MRK +25.73 pp
EQ: +12.0% · MRK: +37.73%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EQ Revenue MRK Revenue EQ Op. Margin MRK Op. Margin Margin Leader
FY2018 N/A $42.3B N/A 14.7% MRK
FY2019 N/A $39.1B N/A 25.2% MRK
FY2020 N/A $41.5B N/A 17.0% MRK
FY2021 N/A $48.7B N/A 26.8% MRK
FY2022 $20M $59.3B -393.9% 24.5% MRK
FY2023 $40M $60.1B -40.2% 0.6% MRK
FY2024 $40M $64.2B -20.1% 26.7% MRK
FY2025 N/A $65.0B N/A 28.1% MRK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRK CONSOLIDATION
61d in phase · OBV DISTRIBUTION
Current IV 30.6%
IV Percentile 28th %ile
Put/Call OI Skew 0.80x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $144.46 · IV 31.1%

MRK Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($14,446)

Compare $14,446 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 31.1% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $145 / $155 Bull Call Spread

Buy 1x $145C · Sell 1x $155C · 31d

Net Entry $340 Debit
T+5d @ +5% Move +$221 (+65%)
Max Risk / Buffer $340 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $135 / $125 Bull Put Spread

Sell 1x $135P · Buy 1x $125P · 31d

Net Entry $149 Credit
Max Credit / Yield +$149 (+17.5% RoM)
Max Risk / Buffer -7.6% Cushion ($851 Mgn)
5d Edge & Liquidity 78% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Asymmetric 1x1x1 ($145C + $143/$130P)

+1x 17d $143P · -1x 59d $130P · +1x 31d $145C

Net Entry $504 Debit
T+5d @ +5% Move +$343 (+16.1% RoM)
Max Risk / Buffer -10.0% Put Cushion ($2,125 Mgn)
5d Edge & Liquidity 9.9x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MRK Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $339.7B market capitalization and 35.2% operating margin.
OpEx & R&D Reinvestment 40.0% of Rev ($27.0B)
90D Engineering Disclosures 0 Published

Investor FAQ EQ vs MRK Key Questions & Quantitative Answers

As of Nov 19, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over Equillium, Inc. (EQ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EQ carries a Unified Composite Score of 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin), whereas MRK carries 50.8/100 (HOLD) at $132.81 (14.8x Forward P/E, 35.2% operating margin). Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile MRK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRK leads the Growth & Scale pillar: EQ posts -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin), compared with MRK at +4.7% YoY revenue growth and -12.0% YoY earnings growth on $67.4B TTM revenue (75.2% gross margin, 35.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EQ cumulative revenue shifted +100.0% while MRK shifted +53.7%. In operating R&D and SG&A reinvestment, EQ deploys N/A (0 90-day corporate R&D disclosures) versus 40.0% of Rev ($27.0B) (0 disclosures) for MRK.

EQ screens cheaper on headline valuation multiples. EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin), whereas MRK trades at 14.8x Forward P/E, 139.2x Trailing P/E, 3.47x PEG, and 5.7x EV/Revenue (21.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EQ (-59.0% ROE) versus MRK (5.1% ROE) capital efficiency.

In options market volatility and institutional positioning, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk). By comparison, MRK carries 30.6% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.80x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 34% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.